Monoclonal Antibody Treatment, Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread

Summary Background Antiviral monoclonal antibodies (mAbs) developed for treatment of COVID-19 reduce the magnitude and duration of viral shedding and can thus potentially contribute to reducing transmission of the causative virus, severe acute respiratory coronavirus 2 (SARS-CoV-2). However, use of these mAbs in combination with a vaccine program has not been considered in public health strategic planning.Methods We developed an agent-based model to characterize SARS-CoV-2 transmission in the US population during an aggressive phase of the pandemic (October 2020 to April 2021), and simulated the effects on infections and mortality of combining mAbs as treatment and post-exposure prophylaxis (PEP) with a vaccine program plus non-pharmaceutical interventions. We also interrogated the impact of rapid diagnostic testing, increased mAb supply, and vaccine rollout.Findings Allocation of mAbs as PEP or targeting those ≥65 years provided the greatest incremental benefits relative to vaccine in averting infections and deaths, by up to 17% and 41%, respectively. Rapid testing, facilitating earlier diagnosis and mAb use, amplified these benefits. The model was sensitive to mAb supply; doubling supply further reduced infections and mortality, by up to two-fold, relative to vaccine. mAbs continued to provide incremental benefits even as proportion of the vaccinated population increased.Interpretation Use of anti-viral mAbs as treatment and PEP in combination with a vaccination program would substantially reduce SARS-CoV-2 transmission and pandemic burden. These results may help guide resource allocation and patient management decisions for COVID-19 and can also be used to inform public health policy for current and future pandemic preparedness.Funding Regeneron Pharmaceuticals..

Medienart:	Preprint

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	bioRxiv.org - (2021) vom: 27. Mai Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Beteiligte Personen:

Kamal, Mohamed A. [VerfasserIn] Kuznik, Andreas [VerfasserIn] Qi, Luyuan [VerfasserIn] Więcek, Witold [VerfasserIn] Hussein, Mohamed [VerfasserIn] Hassan, Hazem E. [VerfasserIn] Patel, Kashyap [VerfasserIn] Obadia, Thomas [VerfasserIn] Toroghi, Masood Khaksar [VerfasserIn] Conrado, Daniela J. [VerfasserIn] Al-Huniti, Nidal [VerfasserIn] Casciano, Roman [VerfasserIn] O’Brien, Meagan P. [VerfasserIn] Barnabas, Ruanne V. [VerfasserIn] Cohen, Myron S. [VerfasserIn] Smith, Patrick F. [VerfasserIn]

Links:	Volltext [kostenfrei]

doi:	10.1101/2021.05.21.21257624

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	XBI020629702